VORICONAZOLE-ZP voriconazole 200mg tablet blister pack

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

voriconazole, Quantity: 200 mg

Disponible des:

Medis Pharma Pty Ltd

Designació comuna internacional (DCI):

Voriconazole

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: croscarmellose sodium; lactose monohydrate; magnesium stearate; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; triacetin; macrogol 3350

Vía de administración:

Oral

Unidades en paquete:

30, 100, 56, 10, 20, 50, 2, 14, 28

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

VORICONAZOLE-ZP is indicated for treatment of the following fungal infections:,Invasive aspergillosis.,Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,Serious fungal infections caused by Scedosporium spp and Fusarium spp.,Other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,Prophylaxis in patients who are at high risk of developing invasive fungal infections. The indication is based on studies including patients undergoing haematopoietic stem cell transplantation. This brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets.

Resumen del producto:

Visual Identification: white, oval biconvex tablets, debossed 'VC200' on one side and plain on the reverse; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius

Estat d'Autorització:

Licence status A

Data d'autorització:

2015-02-02